{"id":"W4386189439","doi":"10.1007/s40120-023-00533-1","title":"Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cégep de Lévis; Selkirk College","funders":"UCB Pharma; National Institutes of Health; Britannia Pharmaceuticals; H. Lundbeck A/S; Newcastle University; Eisai; University of Oxford; Wellcome Trust; Medical Research Council; International Parkinson and Movement Disorder Society; AbbVie; EVER Neuro Pharma; Ministero dell’Istruzione, dell’Università e della Ricerca; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Pfizer","keywords":"Medicine; Parkinson's disease; Open label; Neurology; Internal medicine; Pharmacology; Disease; Adverse effect; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393743,0.001582236,0.002921186,0.000452376,0.0006492658,0.001279664,0.001013972,0.001648579,0.003216493],"category_scores_gemma":[0.001102532,0.0005709605,0.001981525,0.0005184396,0.001126636,0.001129642,0.0003328603,0.003268992,0.0008264627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009965095,"about_ca_system_score_gemma":0.001555824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001289747,"about_ca_topic_score_gemma":0.002944447,"domain_scores_codex":[0.9993091,0.000252414,0.000046843,0.0001376852,0.0001147176,0.0001393043],"domain_scores_gemma":[0.998624,0.000181179,0.0003596052,0.0001248321,0.0001366074,0.0005737806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.80325,0.0867934,0.004675123,0.0008151102,0.001516443,0.0002952429,0.0003733482,0.0008383852,0.04448215,0.00007788958,0.001733432,0.05514945],"study_design_scores_gemma":[0.5466032,0.4276559,0.01981856,0.00004001383,0.0005418226,0.0002655548,0.00005998556,0.0006677647,0.003095665,0.0001045686,0.001108568,0.00003847491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995061,0.001431911,0.0003924489,0.0001559552,0.0000494764,0.001338766,0.0008263868,0.00007135815,0.000672708],"genre_scores_gemma":[0.9912024,0.00133746,0.001200501,0.0005726829,0.0001528565,0.001954508,0.002208936,0.000035827,0.00133481],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003216493,"threshold_uncertainty_score":0.01265943,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04677587415452242,"score_gpt":0.3153436746865626,"score_spread":0.2685678005320402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}